Could a memory drug boost antidepressants? small brain study launches

NCT ID NCT07139834

First seen Jun 25, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This early study is testing whether adding the drug memantine (used for Alzheimer's) to a standard antidepressant can improve how the brain processes memories in people with major depression. Thirty adults aged 18-50 will take an SSRI for 11 weeks, and for the last 6 weeks they will also receive either memantine or a placebo. Researchers will use brain scans and memory tasks to see if the combination works better than the antidepressant alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
escitalopram (or sertraline) and extended-release memantine
What this could lead to
If successful, this could point toward a new way to boost memory and thinking in people with depression by adding memantine to standard antidepressants.
What could go wrong
This is a very small, early-phase study (30 people) focused on brain scans and cognitive tests, not on curing depression. The results may not lead to a new treatment and could fail to show any benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • New York State Psychiatric Institute (NYSPI)

    RECRUITING

    New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.